The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

NCT07023861 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ENROLLING_BY_INVITATION

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Gastric Cancer (GC)
Urothelial Carcinoma (UC)

Interventions

DRUG: 18F-FDG
DRUG: 89Zr-LNCab190
DRUG: 89Zr-LNCab002
DRUG: 89Zr-LNCab072

Sponsor

Affiliated Hospital of Jiangnan University